CD84 CAR T-cells

CD84 CAR T-cells are a second-generation chimeric antigen receptor T-cell therapy engineered to target CD84, a member of the SLAM family (SLAMF5), on the surface of malignant cells. CD84 is highly overexpressed in certain hematologic malignancies, notably acute myeloid leukemia (AML), T-cell acute lymphoblastic leukemia (T-ALL), and B-cell malignancies, while its expression on healthy tissues and hematopoietic stem/progenitor cells (HSPC) is limited. These CAR T-cells are genetically modified to recognize CD84, allowing them to selectively eliminate leukemic blasts while sparing most healthy cells. Preclinical studies demonstrated that CD84 CAR T-cells have potent cytotoxicity against AML, T-ALL, and B-ALL, both in vitro and in patient-derived xenograft (PDX) models, with low risk of myelotoxicity. Early clinical trials are underway for relapsed/refractory AML and T-ALL. Developers are pursuing both monotherapy and combinations, such as dual CD19/CD84 CAR T-cells, to address antigen-negative relapses in B-cell malignancies[1][3][4][5][7].

Other names

CART84CART-84CART 84CD84 chimeric antigen receptor T-cellsCD-84 chimeric antigen receptor T-cellsCD 84 chimeric antigen receptor T-cellsautologous CD84 CAR T cells